WOBURN, Mass. & ORLANDO, Fla.--(BUSINESS WIRE)--Investigators presented data at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) from four clinical trials with ARQ 197, an inhibitor of the c-MET receptor tyrosine kinase under development by ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo Co., Ltd.
